Holen Sie sich die Stockscreener-App
4.485
0.79%
0.035
Handel nachbörslich:
4.49
0.005
+0.11%
Schlusskurs vom Vortag:
$4.45
Offen:
$4.45
24-Stunden-Volumen:
545.69K
Relative Volume:
0.39
Marktkapitalisierung:
$1.72B
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-33.82
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
+3.82%
1M Leistung:
+0.56%
6M Leistung:
-34.81%
1J Leistung:
-31.00%
1-Tages-Spanne:
$4.39
$4.49
1-Wochen-Bereich:
$4.305
$4.655
52-Wochen-Spanne:
$3.82
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.485 | 1.72B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
215.95 | 36.39B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
53.21 | 9.87B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
40.45 | 7.46B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
84.52 | 7.21B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.45 | 6.30B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
Truist Cuts Price Target on GoodRx Holdings to $5.50 From $6.50, Keeps Hold Rating - MarketScreener
GoodRx Announces Date for First Quarter 2025 Earnings Release an - GuruFocus
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call - Bluefield Daily Telegraph
GoodRx Sets Q1 Earnings Date: What Healthcare Investors Should Watch - Stock Titan
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform - Nasdaq
Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineGDRX - ACCESS Newswire
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.18 Average Price Target from Brokerages - MarketBeat
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges - Investing.com Australia
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges By Investing.com - Investing.com South Africa
GoodRx (GDRX) Launches Digital Prescription Service with Hy-Vee - GuruFocus
GoodRx launches new e-commerce experience for prescriptions - Yahoo Finance
GoodRx Introduces New E-commerce Experience for Retail Pharmacies - Seeking Alpha
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
GoodRx Holdings: The Top 7 Influences on Its Performance for 2025 & the Future! - Smartkarma
GoodRx, PBM Price-Fixing MDL Set In Rhode Island - Law360
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital - Yahoo Finance
Do Fundamentals Have Any Role To Play In Driving GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Stock Up Recently? - simplywall.st
GoodRx: Great Value For Patient Investors (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
PBMs Hit With Antitrust Suit Over GoodRx Generics Program - Law360
GoodRx Strengthens Leadership: $100M Revenue Leader Takes President Role - StockTitan
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by US Bancorp DE - Defense World
GoodRx Holdings, Inc. (GDRX): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
GoodRx Holdings, Inc. (GDRX): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Shareholders of GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Wells Fargo & Company Cuts GoodRx (NASDAQ:GDRX) Price Target to $8.00 - Defense World
Levi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Call Transcript - MSN
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc.(GDRX) Shareholders - ACCESS Newswire
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts - Benzinga
Investors who lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class ActionGDRX - ACCESS Newswire
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Decoding GoodRx Holdings Inc (GDRX): A Strategic SWOT Insight - GuruFocus.com
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales - Benzinga
GoodRx Holdings Inc (GDRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
GoodRx Holdings Reports Strong 2024 Financial Results - TipRanks
GoodRx Earnings Call: Growth Amid Challenges - TipRanks
Citi raises GoodRx stock target to $6.75, maintains buy rating By Investing.com - Investing.com South Africa
GoodRx Holdings IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
Citi raises GoodRx stock target to $6.75, maintains buy rating - Investing.com
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics - MSN
Raymond James Reiterates Strong Buy Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider.com
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):